Analyst Price Targets — CRNX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 30, 2026 12:33 pm | — | Stifel Nicolaus | $84.00 | $52.44 | TheFly | Crinetics price target raised to $84 from $75 at Stifel |
| January 12, 2026 10:29 am | Richard Law | Goldman Sachs | $67.00 | $53.25 | TheFly | Crinetics upgraded to Buy from Neutral at Goldman Sachs |
| January 8, 2026 12:45 pm | — | Morgan Stanley | $87.00 | $52.82 | TheFly | Crinetics price target raised to $87 from $80 at Morgan Stanley |
| January 8, 2026 9:26 am | — | China Renaissance Securities (US) Inc. | $105.00 | $53.34 | StreetInsider | Crinetics (CRNX) PT Lowered to $105 at Citizens: Palsonify Experience Positive |
| January 5, 2026 3:25 pm | — | Evercore ISI | $90.00 | $51.26 | TheFly | Crinetics price target raised to $90 from $80 at Evercore ISI |
| January 5, 2026 3:04 pm | Alex Thompson | Stifel Nicolaus | $75.00 | $50.57 | StreetInsider | Stifel Reiterates Buy Rating on Crinetics (CRNX) |
| September 30, 2025 11:49 am | — | Oppenheimer | $87.00 | $43.51 | TheFly | Crinetics price target raised to $87 from $73 at Oppenheimer |
| September 28, 2025 8:42 pm | — | Morgan Stanley | $77.00 | $45.91 | TheFly | Crinetics price target raised to $77 from $65 at Morgan Stanley |
| September 26, 2025 8:39 am | Jonathan Wolleben | JMP Securities | $143.00 | $45.91 | TheFly | Crinetics price target raised to $143 from $86 at Citizens JMP |
| July 10, 2025 9:13 am | Richard Law | Goldman Sachs | $36.00 | $31.99 | TheFly | Crinetics initiated with a Neutral at Goldman Sachs |
Latest News for CRNX
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX - Get Free Report) insider Jeff Knight sold 85,163 shares of the company's stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $40.10, for a total transaction of $3,415,036.30. Following the transaction, the insider owned 105,289 shares of the company's stock,
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation
A director of Crinetics Pharmaceuticals reported that he sold 5,000 shares of the company for a transaction value of approximately $180,761 on March 12, 2026. The sale represented 23.47% of Coelho's direct common stock holdings, reducing direct ownership from 21,300 to 16,300 shares.
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health Surveillance Agency (ANVISA) for PALSONIFY™ (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment of acromegaly in adults. “The…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRNX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.